StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Level 3 Rollforward by Quarter

Level 3 Rollforward — Cash Settlements and Payments ($M) ($M)

QuarterlyAnnual

AbbVie Level 3 Rollforward: $1,062M in Q2 2026, up 23.6% from a year earlier. That is the highest of the 33 quarters on record here.

Latest, Q2 2026
1,062
Period ended Jun 30, 2026
Change on a year earlier
+23.6%
859 in Q2 2025
History
33 quarters
Since Q4 2017
Sources
28
Documents cited below

Where the Q2 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 10-Q (filed 2026-08-03) ↗

Reported in Form 10-Q / 10-K Fair Value Measurements Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLevel 3 Rollforward — Cash Settlements and Payments ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,062+23.6%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 2026722+31.5%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 2025681+26.3%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025776+33.8%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025859+77.1%Form 10-Q (filed 2026-08-03) ↗
Q1 2025Mar 31, 2025549+40.4%Form 10-Q (filed 2026-05-08) ↗
Q4 2024Dec 31, 2024539+12.3%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 2024580+19.6%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 2024485+46.1%Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 2024391+20.3%Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 2023480+50.9%Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 2023485+18.9%Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 2023332+33.3%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023325+1.2%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022318+20.5%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022408+142.9%Form 10-Q (filed 2023-11-06) ↗

Breakdown

What makes up level 3 Rollforward

Cite this data

StockData. (2026). AbbVie Level 3 Rollforward ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-payments

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.